TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of ATEGE-Fresenius Induction in Liver Transplantation Followed by Tacrolimus Weaning.
Brief Summary: This is a randomized, controlled trial in liver transplantation in which conventional immunosuppressive treatment will be compared with a therapeutic strategy consisting in pre-transplant antibody-mediated T cell depletion followed by reduced calcineurin inhibitor usage. The working hypothesis is that antibody induction followed by calcineurin inhibitor minimization may promote development of tolerogenic mechanisms allowing the eventual withdrawal of all immunosuppressive therapy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: ATG (Fresenius Biotech); Assigned to Arm(s): N/A
C: Arm Label: EVR/TAC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Corticosteroids | Arm Label: TAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): EVR/TAC | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): EVR/TAC, TAC | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): EVR/TAC, TAC
D: Arm Label: Group 1: Basiliximab+Belatacept (MI) + MMF; Type: EXPERIMENTAL; Interventions: Drug: Basiliximab, Drug: Belatacept More Intensive (MI), Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 2: Belatacept (MI) + MMF; Type: EXPERIMENTAL; Interventions: Drug: Belatacept More Intensive (MI), Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 3: Belatacept Less Intensive (LI) + MMF; Type: EXPERIMENTAL; Interventions: Drug: Belatacept Less Intensive (LI), Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 4: Tacrolimus + MMF; Type: OTHER; Interventions: Drug: Tacrolimus, Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 5: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Group 4: Tacrolimus + MMF, Group 5: Tacrolimus | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Group 1: Basiliximab+Belatacept (MI) + MMF | Intervention Type: DRUG; Name: Belatacept More Intensive (MI); Assigned to Arm(s): Group 1: Basiliximab+Belatacept (MI) + MMF, Group 2: Belatacept (MI) + MMF | Intervention Type: DRUG; Name: Belatacept Less Intensive (LI); Assigned to Arm(s): Group 3: Belatacept Less Intensive (LI) + MMF | Intervention Type: DRUG; Name: Mycophenolate Mofetil (MMF); Assigned to Arm(s): Group 1: Basiliximab+Belatacept (MI) + MMF, Group 2: Belatacept (MI) + MMF, Group 3: Belatacept Less Intensive (LI) + MMF, Group 4: Tacrolimus + MMF

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial.
Brief Summary: Borderline Personality Disorder (BDP) is a serious mental disorder that affects about 1-2% of the general population, and it is characterized by severe psychosocial impairment and a high mortality rate due to suicide. Currently, the most effective treatments for BPD are psychotherapy (cognitive behavior therapy - CBT -) and pharmacotherapy (often as an important adjunctive role, especially for diminution of symptoms such as affective instability, impulsivity, psychotic-like symptoms and self-destructive behavior). Nevertheless, although several drugs are used in these patients, these drugs induce an improvement of some symptoms but do not cause the remission of BPD. Thus, identification of novel treatments is needed.

The objective of this study is to examine the efficacy of Omacor® ( a mixture of omega-3-acid ethyl esters: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ) for BDP patients receiving CBT. Patients with BDP will be randomly allocated to the three arms of the study: 1- CBT+placebo, 2- CBT+Omacor 1680 mg/d, 3- CBT+Omacor 3360 mg/d. Follow up will last for 12 weeks. Assessment of affective symptoms, impulsivity and aggressivity will be carried out at baseline and at 2, 4, 6, 8, 10 and 12 weeks.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Psychiatric Management | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Intervention Type: BEHAVIORAL; Name: General Psychiatric Management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): 2
B: Arm Label: ASAP Treatment and Brite; Type: EXPERIMENTAL; Interventions: Behavioral: As Safe As Possible, Behavioral: Brite | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: As Safe As Possible; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Brite; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
C: Arm Label: 1; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 2; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 3; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 4; Type: OTHER; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omacor®; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healing Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial
Brief Summary: The investigators are studying whether a brief three-session mind-body workshop helps people with fibromyalgia. The investigators hypothesize that this workshop will significantly improve pain and other symptoms, compared to usual care.


Options:
A: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education
B: Arm Label: Workshop; Type: EXPERIMENTAL; Interventions: Behavioral: Affective Self-Awareness workshop | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Affective Self-Awareness workshop; Assigned to Arm(s): Workshop
C: Arm Label: Tai Chi Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi Intervention | Arm Label: Control Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control Intervention | Intervention Type: BEHAVIORAL; Name: Tai Chi Intervention; Assigned to Arm(s): Tai Chi Intervention | Intervention Type: BEHAVIORAL; Name: Control Intervention; Assigned to Arm(s): Control Intervention
D: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
Brief Summary: Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this.


Options:
A: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Arm Label: Intensive Control of Systolic Blood Pressure (SBP); Type: EXPERIMENTAL; Interventions: Drug: Intensive Control of Systolic Blood Pressure (SBP) | Arm Label: Standard Control of Systolic Blood Pressure (SBP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of Systolic Blood Pressure (SBP) | Intervention Type: DRUG; Name: Intensive Control of Systolic Blood Pressure (SBP); Assigned to Arm(s): Intensive Control of Systolic Blood Pressure (SBP) | Intervention Type: DRUG; Name: Standard control of Systolic Blood Pressure (SBP); Assigned to Arm(s): Standard Control of Systolic Blood Pressure (SBP)
D: Arm Label: Aggressive Blood Pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aggressive Blood Pressure control | Arm Label: Standard Blood Pressure control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aggressive Blood Pressure control; Assigned to Arm(s): Aggressive Blood Pressure control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a randomized trial of an educational intervention to reduce the risk of diabetes among urban American Indian women


Options:
A: Intervention Type: BEHAVIORAL; Name: A lifestyle educational program; Assigned to Arm(s): N/A
B: Arm Label: Mobile phone based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone based intervention; Assigned to Arm(s): Mobile phone based intervention
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Policy and Environmental Change; Type: EXPERIMENTAL; Interventions: Behavioral: Policy and Environmental Change | Intervention Type: BEHAVIORAL; Name: Policy and Environmental Change; Assigned to Arm(s): Policy and Environmental Change
D: Arm Label: Sucrose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sucrose | Arm Label: Aspartame; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Aspartame | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DIETARY_SUPPLEMENT; Name: Aspartame; Assigned to Arm(s): Aspartame

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a randomized trial of an educational intervention to reduce the risk of diabetes among urban American Indian women


Options:
A: Intervention Type: BEHAVIORAL; Name: A lifestyle educational program; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Intensive Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle; Assigned to Arm(s): Intensive Lifestyle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
D: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age 12 Follow-up of Early Preventive Intervention
Brief Summary: To examine the impact of prenatal and infancy home visiting by nurses from child age 2 through 12.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: home visitation | Intervention Type: BEHAVIORAL; Name: home visitation; Assigned to Arm(s): 2
B: Arm Label: Mentor Mothers Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer support and mentoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer support and mentoring; Assigned to Arm(s): Mentor Mothers Intervention
C: Arm Label: Philani Intervention Program; Type: EXPERIMENTAL; Interventions: Behavioral: Philani Intervention Program | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Philani Intervention Program; Assigned to Arm(s): Philani Intervention Program
D: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age 12 Follow-up of Early Preventive Intervention
Brief Summary: To examine the impact of prenatal and infancy home visiting by nurses from child age 2 through 12.


Options:
A: Arm Label: Fruit and Vegetable Intake Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Fruit and vegetable intake in rural youth | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Fruit and vegetable intake in rural youth; Assigned to Arm(s): Fruit and Vegetable Intake Behavioral Intervention
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Communities That Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communities That Care | Intervention Type: BEHAVIORAL; Name: Communities That Care; Assigned to Arm(s): Communities That Care Intervention
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: home visitation | Intervention Type: BEHAVIORAL; Name: home visitation; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pathways; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age 12 Follow-up of Early Preventive Intervention
Brief Summary: To examine the impact of prenatal and infancy home visiting by nurses from child age 2 through 12.


Options:
A: Arm Label: CBI in ED with AMET at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer-delivered Brief Intervention (CBI), Behavioral: Adapted Motivational Enhancement Therapy (AMET) | Arm Label: CBI in ED with EUC at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer-delivered Brief Intervention (CBI) | Arm Label: IBI in ED with AMET at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intervener-delivered Brief Intervention (IBI), Behavioral: Adapted Motivational Enhancement Therapy (AMET) | Arm Label: IBI in ED with EUC at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intervener-delivered Brief Intervention (IBI) | Arm Label: EUC in ED with AMET at 3 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Enhancement Therapy (AMET) | Arm Label: EUC in ED with EUC at 3 months; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Computer-delivered Brief Intervention (CBI); Assigned to Arm(s): CBI in ED with AMET at 3 months, CBI in ED with EUC at 3 months | Intervention Type: BEHAVIORAL; Name: Intervener-delivered Brief Intervention (IBI); Assigned to Arm(s): IBI in ED with AMET at 3 months, IBI in ED with EUC at 3 months | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Enhancement Therapy (AMET); Assigned to Arm(s): CBI in ED with AMET at 3 months, EUC in ED with AMET at 3 months, IBI in ED with AMET at 3 months
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: home visitation | Intervention Type: BEHAVIORAL; Name: home visitation; Assigned to Arm(s): 2
C: Arm Label: Family Spirit Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Family Spirit Intervention | Arm Label: Optimized Standard Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Family Spirit Intervention; Assigned to Arm(s): Family Spirit Intervention
D: Arm Label: Health Education (HE); Type: EXPERIMENTAL; Interventions: Behavioral: Health Education, Behavioral: Questionnaires, Drug: Nicotine Patches | Arm Label: Motivation and Problem Solving (MAPS); Type: EXPERIMENTAL; Interventions: Behavioral: Health Education, Behavioral: Questionnaires, Behavioral: Telephone Counseling Sessions, Drug: Nicotine Patches | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education (HE), Motivation and Problem Solving (MAPS) | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Health Education (HE), Motivation and Problem Solving (MAPS) | Intervention Type: BEHAVIORAL; Name: Telephone Counseling Sessions; Assigned to Arm(s): Motivation and Problem Solving (MAPS) | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Health Education (HE), Motivation and Problem Solving (MAPS)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs
Brief Summary: ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain . The present study addressed the possible role of the Residual Vein Thrombosis in assessing the need for a prolonged anticoagulation.

Methods Patients with a first episode of symptomatic unprovoked or provoked proximal Vein Thrombosis (VT) were given Oral Anticoagulant Treatment (OAT) for 3 months. Residual Vein Thrombosis (RVT), ultrasonographically-detected, will be then assessed. Patients without RVT did not continue OAT, whereas those with RVT will be randomized to either stop or continue OAT for 9 more months. Patients were followed-up prospectively focusing on the study outcomes: occurrence of recurrent venous thromboembolism and major bleeding over a period of at least 12 months after OAT discontinuation.


Options:
A: Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Duration of anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin duration; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sodium warfarin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium warfarin | Intervention Type: DRUG; Name: sodium warfarin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Sodium warfarin; Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: Vitamin K antagonist (Coumarin anticoagulants); Assigned to Arm(s): N/A

Answer: A